青青稞酒(002646.SZ):控股股東與國泰君安開展融資融券業務
格隆匯11月5日丨青青稞酒(002646.SZ)公佈,公司近日收到控股股東華實投資《關於開展融資融券業務的告知函》。華實投資與國泰君安開展融資融券業務,將其持有的公司無限售流通股1200萬股轉入華實投資在國泰君安開立的客户信用交易擔保證券賬户中,該部分股份的所有權未發生轉移。
華實投資目前共持有公司股份約2.71億股,佔公司總股本的60.30%。其中,累計存放於普通證券賬户的公司股份約為2.59億股,佔其所持股份的95.58%,佔公司總股本的57.63%;累計存放於國泰君安客户信用交易擔保證券賬户的公司股份為1200萬股,佔其所持股份的4.42%,佔公司總股本的2.67%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.